Abstract 465TiP
Background
Management of musculo-skeletal cancers patients has changed significantly with change in treatment paradigm from amputation to limb conservation. Limb Salvage Surgery (LSS) is now the standard of care. Moreover, increase in survival rates following advancement in the available multimodality treatment has lead to increased interest regarding the quality of life (QOL) and functional outcomes of the survivor patients. Unfortunately, all the QoL studies in published literature pertain to western population. This study aims to determine the functional outcomes and quality of life after performing limb salvage surgery in extremity sarcoma patients in Indian population in tertiary care hospital.
Trial design
Observational study Inclusion criteria- extremity sarcoma patients treated with either limb salvage surgery or amputation between the year Jan 2017 to Dec 2022. Extremities sarcomas includes bone tumors and soft tissue sarcomas between 14 and 50 years of age. Exclusion criteria-Non extremities sarcoma patients and patients with rotationplasty / turn-o-plasty procedures done Patients’ baseline socio-demographic and clinical characteristics (age, gender, morphology and the type of surgical intervention) as well as orthopedic or oncological complications occurring during the follow-up will be derived from the medical record. Questionnaires concerning QoL and functional outcomes which will be sent by post / telephonically or an interview with the investigators on outpatient basis. Assessment tools: Functional outcome will be measured using the Toronto extremity salvage score, Musculoskeletal tumor society score while Quality of life will be assessed using the EORTC QLQ-C30 QoL scale. Statistical Analysis: Descriptive analysis of quantitative parameters will be expressed as means and standard deviation. Categorical data will be expressed as absolute number and percentage. Independent Student's t-test will be used for testing of mean difference between independent groups. Cross tables will be generated and Chi square test will be used for testing of associations. P-value < 0.05 will be considered statistically significant. All analysis will be done using SPSS software, version 24.0.
Clinical trial identification
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
461P - Spectrum of immune related adverse events (irAE) on treatment with checkpoint inhibitors and its association with survival: A real-world experience from India
Presenter: Nitin Murthy
Session: Poster viewing 06
462P - Limited duration of treatment with checkpoint inhibitors in complete responders, yet prolonged survival: A real-world study from India
Presenter: Nitin Murthy
Session: Poster viewing 06
463P - Cost effectiveness of palbociclib and ribociclib in metastatic breast cancer in India using ICER and QALY
Presenter: Krishnamani Kalpathi
Session: Poster viewing 06
464TiP - Phase III study of adjuvant encorafenib plus binimetinib vs placebo in fully resected stage IIB/C BRAFV600-mutated melanoma: COLUMBUS-AD study design
Presenter: Alexander van Akkooi
Session: Poster viewing 06
YO2 - A case of locally advanced breast cancer with biomarker conversion successfully treated with neoadjuvant chemotherapy-immunotherapy combination
Presenter: Long Nguyen
Session: Poster viewing 06
YO3 - Metastatic Breast cancer to esophagus: A case report and review of literature
Presenter: Bhuvana J
Session: Poster viewing 06
YO4 - Succinate Dehydrogenase deficient GISTs is a diagnostic and therapeutic dilemma? : A case report.
Presenter: Nurazzahra Kamarudin
Session: Poster viewing 06
YO5 - Complete Radiologic and Pathologic Response in a Metastatic Gallbladder Adenocarcinoma Patient treated with Checkpoint Inhibitor/Chemotherapy Combination: A Case Report
Presenter: Tisha Gay Tancongco
Session: Poster viewing 06
YO7 - Orbital Metastasis in Prostrate Cancer: A Case Report
Presenter: Shabnam Rehman
Session: Poster viewing 06
YO10 - BRCA2 Mutated Recurrent Adult Granulosa Cell Tumor Treated with PARP Inhibitor
Presenter: Debapriya Mondal
Session: Poster viewing 06